The Board of Directors of NorDiag ASA has today approved the financial statements for 2011.

The statements are adjusted compared to the preliminary and unaudited 2011 results reported by NorDiag ASA on February 16 2012. The adjustments mainly relates to impairment and a write down of NOK 47.5 million related to patents, goodwill and capitalized development costs. The impairment arises from the Company's financial situation, and that the operating revenues projections are based on conservative estimates due to revenue delays. The write down has no cash implications.

For further information, please contact:
CEO Mårten Wigstøl,  Phone: +47 911 65775
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNAfrom difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 29.15 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.

Read the notice in Norwegian here.